

VEGF R3/FLT4
Catalog # PVGS1817**Specification**

VEGF R3/FLT4 - Product Information

Primary Accession [P35916-1](#)
Species
Human

Sequence
Tyr25-Ile776

Purity
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level
Less than 1EU per µg by the LAL method.

Biological Activity
Immobilized VEGF-C, His Tag at 1 µg/ml (100 µl/Well) on the plate can bind VEGF R3/FLT4 hFc Chimera, Human (Cat.No.: Z03968)

Expression System
HEK293

Theoretical Molecular Weight
111.3 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5).**

Reconstitution
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 µg/ml.

Storage & Stability
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

VEGF R3/FLT4 - Additional Information

Target Background
Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors.

VEGF R3/FLT4 - Protein Information

VEGF R3/FLT4 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

VEGF R3/FLT4 - Images